These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23072897)

  • 21. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy.
    Degli Esposti L; Desideri G; Saragoni S; Buda S; Pontremoli R; Borghi C
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):951-61. PubMed ID: 27555289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare-related impact of gout in hospitalized patients in Spain.
    Benavent D; Peiteado D; Martinez-Huedo MÁ; Hernandez-Hurtado M; Balsa A; de Miguel E
    Sci Rep; 2021 Jun; 11(1):13287. PubMed ID: 34168227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the cost of early intervention in psychosis: a systematic review.
    Amos A
    Aust N Z J Psychiatry; 2012 Aug; 46(8):719-34. PubMed ID: 22696550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
    Wood R; Fermer S; Ramachandran S; Baumgartner S; Morlock R
    J Rheumatol; 2016 Oct; 43(10):1897-1903. PubMed ID: 27036386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing attacks of acute gout when introducing urate-lowering therapy: a systematic literature review.
    Seth R; Kydd AS; Falzon L; Bombardier C; van der Heijde DM; Edwards CJ
    J Rheumatol Suppl; 2014 Sep; 92():42-7. PubMed ID: 25180127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
    Friedman M; Menjoge SS; Anton SF; Kesten S
    Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gout in the elderly--a population health study.
    Hanly JG; Skedgel C; Sketris I; Cooke C; Linehan T; Thompson K; van Zanten SV
    J Rheumatol; 2009 Apr; 36(4):822-30. PubMed ID: 19286852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Social costs of the most common inflammatory rheumatic diseases in Mexico from the patient's perspective].
    Mould-Quevedo J; Peláez-Ballestas I; Vázquez-Mellado J; Terán-Estrada L; Esquivel-Valerio J; Ventura-Ríos L; Aceves-Avila FJ; Bernard-Medina AG; Goycochea-Robles MV; Hernández-Garduño A; Burgos-Vargas R; Shumski C; Garza-Elizondo M; Ramos-Remus C; Espinoza-Villalpando J; Alvarez-Hernández E; Flores-Alvarado D; Rodríguez-Amado J; Casasola-Vargas J; Skinner-Taylor C;
    Gac Med Mex; 2008; 144(3):225-31. PubMed ID: 18714591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health economic burden of patients with restless legs syndrome in a German ambulatory setting.
    Dodel R; Happe S; Peglau I; Mayer G; Wasem J; Reese JP; Giani G; Geraedts M; Trenkwalder C; Oertel WH; Stiasny-Kolster K
    Pharmacoeconomics; 2010; 28(5):381-93. PubMed ID: 20297866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, humanistic, and economic outcomes of gout.
    Brixner DI; Ho MJ
    Am J Manag Care; 2005 Nov; 11(15 Suppl):S459-64; quiz S465-8. PubMed ID: 16300460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febuxostat for gout.
    Drug Ther Bull; 2010 Jul; 48(7):78-82. PubMed ID: 20631196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.